N-Ethyl-N-[3-(propylamino)propyl]propane-1,3-diamine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Ethyl-N-[3-(propylamino)propyl]propane-1,3-diamine
• 英文别名: N-ethyl-N'-[3-(propylamino)propyl]propane-1,3-diamine
• 化学式: C₁₁H₂₇N₃
• 分子量: 201.35
• InChiKey: ZFYULDAPZWEGGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  36.1
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds
  申请人：Marton J. Laurence

  公开号：US20070232677A1

  公开（公告）日：2007-10-04

  This disclosure relates to methods of inhibiting vascular hyperplasia using polyamines, polyamine analogs, and conformationally restricted polyamine analogs, or a conjugate of a polyamine, polyamine analog, or conformationally restricted polyamine analog. Polyamines, polyamine analogs, conformationally restricted polyamine analogs, and conjugates thereof are useful in reducing stenosis and restenosis of blood vessels and grafts.

  本公开涉及使用多胺，多胺类似物和构象限制多胺类似物或多胺，多胺类似物或构象限制多胺类似物的共轭物来抑制血管增生的方法。多胺，多胺类似物，构象限制多胺类似物及其共轭物在减少血管和移植物的狭窄和再狭窄方面非常有用。
• Polyamines and their use in therapy
  申请人：Cellgate, Inc.

  公开号：EP1698629A2

  公开（公告）日：2006-09-06

  Novel conformationally restricted polyamine analogs are provided, as well as compositions comprising these novel polyamine analogs. Methods of using the novel polyamine analogs in treatment of diseases such as cancer are also provided. Also provided is a method of delivering these analogs specifically to tumor cells by covalently attaching polyamine analogs to porphyrin compounds, along with novel polyamine-porphyrin covalent conjugates.

  本文提供了构象受限的新型多胺类似物以及包含这些新型多胺类似物的组合物。还提供了使用新型多胺类似物治疗癌症等疾病的方法。此外，还提供了一种通过将多胺类似物与卟啉化合物共价连接，以及新型多胺-卟啉共价结合物，将这些类似物特异性地递送至肿瘤细胞的方法。
• COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS
  申请人：Pathologica LLC

  公开号：EP3473247A1

  公开（公告）日：2019-04-24

  The present invention relates to an oral pharmaceutical composition, comprising methylglyoxal bis(guanylhydrazone) (MGBG) together with at least one oral pharmaceutically acceptable excipient, for use in the treatment or delaying the onset or development of multiple sclerosis when orally administered to a subject.

  本发明涉及一种口服药物组合物，包括甲基乙二醛双（鸟苷腙）（MGBG）和至少一种口服药物可接受赋形剂，用于口服给受试者治疗或延缓多发性硬化症的发作或发展。
• MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS
  申请人：Pathologica LLC

  公开号：EP3831372A1

  公开（公告）日：2021-06-09

  Disclosed herein are new oral pharmaceutical compositions of SAMDC inhibitors, polyamine analogs, and polyamine biosynthesis inhibitors, and their application for the treatment of conditions including demyelinating diseases, autoimmune disorders affecting the nervous system, and other neurodegenerative conditions.

  本文公开了SAMDC抑制剂、多胺类似物和多胺生物合成抑制剂的新型口服药物组合物，以及它们在治疗脱髓鞘疾病、影响神经系统的自身免疫性疾病和其他神经退行性疾病等疾病中的应用。
• Conformationally restricted polyamine analogs as disease therapies
  申请人：——

  公开号：US20040235962A1

  公开（公告）日：2004-11-25

  Novel conformationally restricted polyamine analogs are provided, as well as compositions comprising these novel polyamine analogs. Methods of using the novel polyamine analogs in treatment of diseases such as cancer are also provided. Also provided is a method of delivering these analogs specifically to tumor cells by covalently attaching polyamine analogs to porphyrin compounds, along with novel polyamine-porphyrin covalent conjugates.

  本文提供了构象受限的新型多胺类似物以及包含这些新型多胺类似物的组合物。还提供了使用新型多胺类似物治疗癌症等疾病的方法。此外，还提供了一种通过将多胺类似物与卟啉化合物共价连接，以及新型多胺-卟啉共价结合物，将这些类似物特异性地递送至肿瘤细胞的方法。